Table 2.
Pathological response of patients who received neoadjuvant chemotherapy and immunotherapy.
| ID | Histology | PD-L1 (%) | Tumor size (cm) | Nodal status | Pathological response | Junker Regression | Pathological assessment according to IASLC (%) | DFS (months) | Recurrence | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopsy | Surgery | Biopsy | Surgery | Biopsy | Surgery | Tumor | Necrosis | Stroma | ||||||
| 1 | Squamous | 95 | 90 | 9.6 | 3.5 | 2 | 0 | PR | IIa | 50 | 0 | 50 | 22.30 | No |
| 2 | Adenocarcinoma | 0 | 100 | 6.1 | 4.5 | 1 | 0 | PR | IIa | 40 | 10 | 50 | 9.31 | No |
| 3 | Adenocarcinoma | 90 | 90 | 3.8 | 2.4 | 2 | 2 | PR | IIa | 25 | 0 | 75 | 12.13 | Yes |
| 4 | Squamous | 75 | 95 | 6.3 | 4.8 | 2 | 0 | PR | IIa | 15 | 50 | 35 | 17.48 | No |
| 5 | Squamous | 0 | 100 | 5 | 5.3 | 1 | 0 | MPR | IIb | 5 | 65 | 30 | 18.16 | No |
| 6 | Adenocarcinoma | 90 | 100 | 3.2 | 2.4 | 2 | 0 | MPR | IIb | 5 | 0 | 95 | 15.54 | Yes |
| 7 | Adenocarcinoma | 20 | 70 | 6 | 3.4 | 2 | 0 | MPR | IIb | 5 | 35 | 60 | 9.31 | No |
| 8 | Adenocarcinoma | 90 | 70 | 6.6 | 6 | 2 | 0 | MPR | IIb | 5 | 20 | 75 | 9.25 | Yes |
| 9 | Squamous | 60 | NAa | 3 | 1.3 | 1 | 0 | pCR | III | 0 | 0 | 100 | 1.67 | No |
| 10 | Squamous | NAa | NAa | 4.3 | 0 | 2 | 0 | pCR | III | 0 | 0 | 100 | 30.20 | No |
| 11 | Squamous | 20 | NAa | 2.1 | 1.7 | 2 | 0 | pCR | III | 0 | 20 | 80 | 14.66 | No |
MPR major pathological response, pCR pathological complete response, PR partial response.
aNot available because of insufficient tissue.